Cargando…

Crohn's disease of the gastrointestinal tract /

Detalles Bibliográficos
Autor principal:	Schachter, Howard
Otros Autores:	Kirsner, Joseph B., 1909- (joint author.)
Formato:	Libro
Lenguaje:	English
Publicado:	New York : Wiley, c1980.
Colección:	Clinical gastroenterology monographs series.
Materias:	Enfermedad de Crohn

Ejemplares similares

Inflammatory bowel disease /
Publicado: (2000)

Enfermedad inflamatoria intestinal
Publicado: (2001)

Aspectos endoscópicos de la enfermedad inflamatoria intestinal /
por: Barreto Zúñiga, Rafael
Publicado: (2014)

Enfermedad diarreica y desnutrición : actualización clínica
Publicado: (1987)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Síndrome de intestino irritable y otros trastornos relacionados : fundamentos biopsicosociales /
Publicado: (2010)

Panel de expertos sobre el síndrome del intestino irritable.
Publicado: (2010)

Interpretando el tracto digestivo irritable : los trastornos funcionales gastrointestinales
por: Thompson, W. Grant
Publicado: (2012)

Guía clínica para los transtornos asociados con el gluten /
por: Fasano, Alessio
Publicado: (2014)

Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
por: Monteleone, G., et al.
Publicado: (2016)

Contemporary diagnosis and management of irritable bowel syndrome /
por: Drossman, Douglas A.
Publicado: (2002)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease
por: van Haaften, W. T., et al.
Publicado: (2017)

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study
por: Panés, Julián, et al.
Publicado: (2019)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease
por: Lansdorp, Corine A., et al.
Publicado: (2020)

Avances en enfermedad diarreica y desequilibrio hidroelectrolitico
Publicado: (1991)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease
por: Vaughan, Rose, et al.
Publicado: (2022)

Association between high dietary intake of the n−3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease
por: Chan, S. S. M., et al.
Publicado: (2014)

The Management and prevention of diarrhoea : practical guidelines.
Publicado: (1993)

Obstrucción intestinal/
por: Welch, Claude E.
Publicado: (1959)

Manejo y prevención de la diarrea : pautas prácticas.
Publicado: (1994)

Development of vaccines and drugs against diarrhea: 11th Nobel Conference, Stockholm 1985
Publicado: (1986)

Síndromes diarreicos
Publicado: (1987)

Preguntas y respuestas sobre diarrea /
por: Pajares Villarroya, R.

Celíacos : se descubren nuevos causantes de la enfermedad : los cereales no son los únicos protagonistas
por: Passera, Andrea Helena
Publicado: (2015)

A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a UK tertiary IBD centre
por: Meade, Susanna, et al.
Publicado: (2022)

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn’s disease in patients with positive results
por: Zhao, Yujie, et al.
Publicado: (2020)

The Lewis score or the capsule endoscopy Crohn’s disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn’s disease?
por: Yablecovitch, Doron, et al.
Publicado: (2018)

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
por: Lenti, Marco Vincenzo, et al.
Publicado: (2021)

Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn’s disease
por: Chen, Rirong, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers
por: Logan, Michael, et al.
Publicado: (2020)

Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014)

The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn’s disease in patients with negative ileocolonoscopy
por: Carter, Dan, et al.
Publicado: (2018)

Diseases of the liver and biliary tract /
Publicado: (1992)

Diseases of the kidney and urinary tract.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_gu6r5qbj7imnlunug237t482ul